Today on Drug Discovery & Development
Scientists develop new machine-learning model to predict immunogenic neoantigens
Researchers at Cleveland Clinic’s Global Center for Immunotherapy, in collaboration with Bristol Myers Squibb, have published a comprehensive study on how the immune system remodels the tumor microenvironment in response to immune checkpoint therapy. This research represents the most detailed analysis of this process to date. Under the leadership of Timothy Chan, MD, PhD, Chair…5 Key Questions in Conducting Global Usability Studies
By Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A sleek design means little if users struggle to use it effectively. This article explores five key questions for planning global usability tests and the benefits of partnering with experts. 1. What is the Right Sampling…Drug Discovery and Development See More >
The roadmap to effective AI-driven drug development
Generative artificial intelligence (GAI) has captivated the world, and for good reason. Platforms like ChatGPT have demonstrated capabilities that gave the general public a deeper understanding of AI’s capabilities. AI, too, is showing potential in drug discovery. From designing novel drug molecules to predicting protein structures, AI is offering a new path forward, potentially accelerating…
Sponsored Content See More >
Genomics/Proteomics See More >
St. Jude pioneers gene editing and structural biology to advance pediatric research
After establishing her lab at Cornell in 2019 and achieving notable success with publications in top journals, Liz Kellogg, Ph.D., associate member in the department of Structural Biology at St. Jude Children’s Research Hospital received a unique opportunity. St. Jude Children’s Research Hospital had embarked on a major expansion of its structural biology and genome…
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Athos Therapeutics chooses Vultr’s private cloud to power AI drug discovery engine
Deep Genomics announces key hires, expands operations in Cambridge, Mass.
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
Infectious Disease See More >
Moderna and Pfizer win approval for KP.2 vaccine as KP.3 variants account for about half of current cases
The FDA has approved Moderna’s and Pfizer’s updated COVID-19 vaccines targeting the KP.2 variant, an offshoot of the Omicron strain that was dominant in the U.S. in May 2024. More recently, KP.3 variants are gaining ground. As of August 20, 2024, CDC Nowcast projections estimate KP.3.1.1 accounts for approximately 37% of new COVID-19 cases in…
Moderna’s single-dose mRNA RSV vaccine, mRESVIA, gains FDA approval for adults 60+
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Longevity biotech gaining momentum as demographic shifts drive demand for healthy aging
Public vs. private: Who’s leading the charge in H5N1 preparedness?
Oncology See More >
Q&A: Oracle launches new cloud service to analyze global oncology treatment trends
Traditionally, only a small fraction of oncology drugs make it from phase 1 to commercialization. And biopharmaceutical companies continue to face significant challenges in understanding how new oncology drug approvals affect treatment patterns and market share. To deal with such hurdles, Oracle has recently launched CancerMPact Treatment Architecture Trends (PDF overview here), a resource that…